Our shared service offers standardized MRI imaging protocols for
single-site and multi-site cancer clinical studies. We also offer advanced
image processing to extract quantitative biomarker information from
For more information, please contact Dr. Natarajan Raghunand .
DCE-MRI in a Phase I Study of an Anti-Angiogenic Agent.
A significant decrease in Ktrans was observed in the spleen at the end of a 24 h drug infusion, indicating anti-VEGF activity.
DCE-MRI in a Phase I Study of an Anti-Vascular Agent.
A significant decrease in Ktrans was observed in the tumor at the end of a 4 h drug infusion. In this study, DCE-MRI showed promise as a pharmacodynamic marker of drug activity.